Kiora Pharmaceuticals Files Q2 2025 10-Q

Ticker: KPHMW · Form: 10-Q · Filed: Aug 8, 2025 · CIK: 1372514

Kiora Pharmaceuticals Inc 10-Q Filing Summary
FieldDetail
CompanyKiora Pharmaceuticals Inc (KPHMW)
Form Type10-Q
Filed DateAug 8, 2025
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, SEC filing, compliance, quarterly report

Related Tickers: KPRX

TL;DR

Kiora Pharma (KPRX) filed its 10-Q for June 30, 2025, confirming compliance. All good.

AI Summary

Kiora Pharmaceuticals, Inc. filed its quarterly report for the period ending June 30, 2025. The company is registered in Delaware and its common stock trades under the symbol KPRX on The Nasdaq Capital Market. Kiora has confirmed it has filed all required reports for the preceding 12 months and has been subject to these filing requirements for the past 90 days, also submitting all Interactive Data Files electronically.

Why It Matters

This filing confirms Kiora Pharmaceuticals' compliance with SEC reporting requirements, providing investors with up-to-date financial and operational information.

Risk Assessment

Risk Level: low — This filing is a routine quarterly report and does not contain new material adverse information.

Key Players & Entities

  • KIORA PHARMACEUTICALS, INC. (company) — Registrant
  • June 30, 2025 (date) — Quarterly period end date
  • Delaware (jurisdiction) — State of incorporation
  • KPRX (ticker) — Trading symbol for common stock
  • The Nasdaq Capital Market (exchange) — Exchange where common stock is registered

FAQ

What is the primary purpose of this Form 10-Q filing?

The primary purpose is to provide a quarterly report on the financial and operational status of Kiora Pharmaceuticals, Inc. for the period ended June 30, 2025.

On which exchange is Kiora Pharmaceuticals' common stock traded?

Kiora Pharmaceuticals' common stock is traded on The Nasdaq Capital Market.

What is the trading symbol for Kiora Pharmaceuticals?

The trading symbol for Kiora Pharmaceuticals is KPRX.

Has Kiora Pharmaceuticals filed all required reports for the preceding 12 months?

Yes, the filing indicates that Kiora Pharmaceuticals has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.

Has Kiora Pharmaceuticals submitted all required Interactive Data Files electronically?

Yes, the filing indicates that Kiora Pharmaceuticals has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.

Filing Stats: 4,522 words · 18 min read · ~15 pages · Grade level 17.6 · Accepted 2025-08-08 07:01:45

Key Financial Figures

  • $0.01 — ange on which registered Common Stock, $0.01 par value KPRX The Nasdaq Capital Marke

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 4 Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) for the Three and Six Months Ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity (unaudited) for the Three and Six Months Ended June 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows (unaudited) for the Six Months Ended June 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements (unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 33

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 34

SIGNATURES

SIGNATURES 35 1 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The forward-looking statements are principally, but not exclusively, contained in "Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations." These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management's confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "goal," "foreseeable," "see," "estimate," "project," "intends," "think," "potential," "objective," "optimistic," "strategy," and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the timing and success of preclinical studies and clinical trials conducted by us and our development partners; the ability to obtain and maintain regulatory approval of our product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and com

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements KIORA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2025 (unaudited) December 31, 2024 ASSETS Current Assets: Cash and Cash Equivalents $ 1,028,324 $ 3,792,322 Short-Term Investments 19,637,812 22,999,760 Prepaid Expenses and Other Current Assets 957,095 2,042,487 Collaboration Receivables 2,418,022 601,197 Tax Receivables 696,002 270,246 Total Current Assets 24,737,255 29,706,012 Non-Current Assets: Property and Equipment, Net 106,843 5,232 Restricted Cash 4,461 4,057 Intangible Assets and In-Process R&D, Net 6,687,100 6,687,100 Operating Lease Right-of-Use Assets 349,017 57,170 Other Assets 61,007 24,913 Total Assets $ 31,945,683 $ 36,484,484 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts Payable $ 282,537 $ 415,590 Accrued Expenses 2,540,493 4,588,657 Accrued Collaboration Credit 219,625 981,111 Operating Lease Liabilities 143,327 23,355 Total Current Liabilities 3,185,982 6,008,713 Non-Current Liabilities: Contingent Consideration 4,604,456 4,191,490 Deferred Tax Liability 490,690 490,690 Deferred Collaboration Revenue 1,250,000 — Non-Current Operating Lease Liabilities 287,079 33,815 Total Non-Current Liabilities 6,632,225 4,715,995 Total Liabilities 9,818,207 10,724,708 Commitments and Contingencies (Note 8) Stockholders' Equity: Preferred Stock, $ 0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at June 30, 2025 and December 31, 2024, respectively 4 4 Common Stock, $ 0.01 Par Value: 150,000,000 shares authorized; 3,433,491 and 3,000,788 shares issued and outstanding at June 3

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.